ASSOCIATION OF CHINESE AMERICANS IN CANCER RESEARCH

Association of Chinese Americans in Cancer Research

Newsletter

Newsletter June 2026

Inside this issue:

Message from the past President

Dear ACACR members and friends,

As I conclude my term as President of the Association of Chinese Americans in Cancer Research (ACACR), I am pleased to reflect on several recent milestones that highlight the continued growth, excellence, and strong sense of community within our society.

A major accomplishment this spring was the successful 2026 Joint Annual Meeting with the US Chinese Anti-Cancer Association (USCACA), held on April 18, 2026, at the University of California San Diego. The meeting brought together investigators, clinicians, trainees, and industry partners from across the country for a highly engaging day of scientific exchange and collegial interaction. I would like to extend my heartfelt appreciation to our local hosts, Drs. Jing Yang and Emily Wang, whose dedication and hard work were essential to the success of this event.

One of the highlights of the meeting was the presentation of the 2026 ACACR Tony Hunter Award in Cancer Research. We were honored to recognize James Chen as the Senior Investigator Awardee for his pioneering discovery of cGAS as the cytosolic DNA sensor that activates innate immune responses, a landmark finding with profound impact on cancer biology and immunology. We also proudly recognized Jun Wang as the Junior Investigator Awardee for his outstanding contributions to cancer immunology. Please join me in congratulating both awardees on these well-deserved honors.

I am equally delighted to celebrate the remarkable achievements of our ACACR members beyond this meeting. Chuan He, the 2025 Tony Hunter Senior Investigator Awardee, was recently elected to the National Academy of Sciences, and James Chen was also honored with the prestigious Japan Prize. These accomplishments underscore the extraordinary scientific leadership represented within our ACACR community.

Serving as ACACR President has been a tremendous honor and a deeply rewarding experience. I am sincerely grateful to our executive leadership team—Drs. Wei Xu, Erxi Wu, and Lanjing Zhang—as well as the many members and volunteers whose dedication has advanced ACACR's mission. I am confident that under the new leadership of Dr. Wei Xu, ACACR will continue to flourish and reach even greater heights in the years ahead.

With gratitude and best wishes,

Boyi Gan, Ph.D.

Past President, ACACR
N.G. and Hellen T. Hawkins
Distinguished Professor
for Cancer Research
Department of Experimental Radiation Oncology
The University of Texas MD Anderson Cancer Center

President's Welcome Message

Dear ACACR members and friends,

It is my great honor and privilege to serve as President of the Association of Chinese Americans in Cancer Research (ACACR) for the 2026–2028 term. I am deeply grateful for the trust our community has placed in me, and I am committed to leading this organization with dedication, vision, and a spirit of collaboration.

ACACR has been built on the extraordinary efforts of those who came before us. I extend my heartfelt thanks to our immediate past president, Dr. Boyi Gan, and all former leadership for establishing such a strong foundation. I am equally grateful to our outstanding Executive Committee (Erxi Wu and Qing Zhang, presidents elect; Xiaoqi Liu, Secretary; Wenwei Hu, Treasurer; Mushui Dai, Newsletter), and board members whose tireless service makes this organization thrive.

As we embark on this new chapter together, I am energized by a clear set of priorities:

Investing in the next generation. Supporting junior faculty and early-career scientists is central to our mission. I am thrilled to announce our inaugural **ACACR Career Development Workshop in Cancer Research**, hosted by Dr. Shaomeng Wang, Duxin Sun, Weiping Zou, at the University of Michigan, **August 28–30, 2026**, in Ann Arbor. This two-day intensive program will offer guaranteed oral presentation opportunities to all assistant professors, as well as sessions on grant-writing strategies, career development paths, leadership planning, and professional networking. The workshop has already garnered enthusiastic support from department chairs and leaders across major research institutions nationwide. Registration is now open at ACACR.org — ACACR membership is required, and space is limited.

Strengthening our community. ACACR's greatest asset is the collective power of our members. I am committed to expanding opportunities for scientific exchange, mentorship, and collaboration — both within our annual AACR satellite meeting and through new initiatives throughout the year.

Growing our impact. We will continue to deepen our alliance with AACR and other leading cancer organizations, amplify Chinese American voices in cancer research, and welcome scientists of all backgrounds who share our commitment to preventing and curing cancer.

I look forward to working with each of you, as members, collaborators, sponsors, and friends, to advance ACACR's mission and leave a lasting mark on cancer research.

With warm regards and excitement for what lies ahead,

Wei Xu, Ph.D.
President, ACACR (2026–2028)

Marian A. Messerschmidt Professor of Oncology
University of Wisconsin-Madison

2026 Joint Meeting of ACACR and USCACA (also see: https://acacr.org/web/meetings.php)

When: 1:30 – 7:30 pm, Saturday, April 18, 2026
Where: MET Lower Auditorium, T. Denny Sanford Medical Education and Telemedicine Center, University of California San Diego 9500 Gilman Dr, La Jolla

Agenda

1:30 – 2:00 pm	Registration/check-in/vendor table setup
2:00 – 2:10	Welcome messages by Dr. Boyi Gan (ACACR President, MD Anderson Cancer Center) and Dr. Shi-Yong Sun (USCACA President, Emory University)
2:10 – 2:15	Announcement of 2026 Winners of Tony Hunter Award in Cancer Research by Award Committee Chair, Dr. Boyi Gan, ACACR President, MD Anderson Cancer Center
2:15 – 3:00	Keynote Speech (virtual): Dr. **Zhijian "James" Chen**, UT Southwestern Medical Center, Tony Hunter Award Lecture (Senior Investigator Awardee), introduced by Dr. Boyi Gan Title: TBD
3:00 – 3:25	Dr. Jun Wang, New York University, Tony Hunter Award Lecture (Junior Investigator Awardee), introduced by Dr. Wei Xu. Award presentation by Dr. Tony Hunter. Title: Probing novel immune feedback modulators for next-generation immunotherapies
3:25 – 3:35	AACR representative brief speech: Dr. William Pao, (Member of AACR Board of Directors, and Chair, the AACR Asian/AANHPI Task Force)
3:35 – 4:15	USCACA Award Session, Dr. Shi-Yong Sun, Emory University. USCACA Outstanding Young Chinese Scholar Awards Announcement and Presentations (Dr. Xuefeng Liu, The Ohio State University) Brief presentation by Dr. Jinsong Liu, MD Anderson Cancer Center
4:15 – 4:35	Coffee break (Group Photo)
4:35 – 5:00	Business meeting of the two societies, chaired by Boyi Gan, ACACR President 1. Update on ACACR Publication (*Genes & Disease*): Dr. Zhenghe Wang, Case Western Reserve University and Dr. Tong-Chuan He, University of Chicago 2. ACACR Annual Finance Report: Dr. Wenwei Hu, ACACR Treasurer (2026-2028), Rutgers Cancer Institute
5:10 – 5:40	Sponsor presentations, chaired by ACACR General Secretary, Dr. Erxi Wu, Baylor College of Medicine. Gold Sponsors (3 min each): Metware Biotechnology Inc (MetwareBio), Woburn, MA MedChemExpress (MCE), Monmouth Junction, NJ; RayBiotech, Peachtree Corners, GA; TargetMol, Wellesley Hills, MA; KYINNO Biotechnology, Woburn, MA; Massachusetts Biological Instruments Co. (MBI), Boston, MA; RWD Life Science Co., Ltd., Sugar Land, TX
5:40 – 5:45	Concluding remarks, Dr. Wei Xu, ACACR President-elect, University of Wisconsin-Madison
5:45 – 8:00	Networking/Buffet Dinner

Organizing committee:

Boyi Gan, Wei Xu, Shi-Yuan Cheng, Xuefeng Liu, Shi-Yong Sun, Erxi Wu, Lanjing Zhang, Lin Zhang, Jing Yang, Emily Wang

Dr. Boyi Gan, ACACR president 2024-2026

Dr. Wei Xu, ACACR current president

Dr. Shi-Yong Sun, USCACA president

Dr. Zhijiang "James" Chen, Keynote Speech

Dr. Jun Wang, Tony Hunter Award Lecture

Tony Hunter Award presentation

Dr. Wenwei Hu, Annual Finance report

Dr. William Pao, AACR representative brief speech

Dr. Jinsong Liu, USCACA Award session

Dr. Gen-Sheng Feng, ACACR president 2023-2024

Dr. Zhenghe Wang
Updating on ACACR Journal, Genes & Diseases

Dr. Tony Hunter

All attendees

Members' Research Highlights

Dr. **Boyi Gan** at MD Anderson Cancer Center revealed a metabolic mechanism of radioresistance driven by DHODH-mediated ferroptosis defense and provided a rationale for combining DHODH inhibitors with radiotherapy and immunotherapy in lung cancer and potentially other solid tumors (***Cancer Research***, 2026; https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-25-3728/782685/DHODH-Mediated-Suppression-of-Ferroptosis-Supports?guestAccessKey=). His team also discussed how to target metabolic cell death in cancer therapy (***Nature Reviews Cancer***, 2026; https://www.nature.com/articles/s41568-025-00879-8).

Dr. **Xiaoling Li** and her team at NIEHS of NIH identified a key role of the microbiota in mediating host NAD^+ biosynthesis through the deamidated NAD^+ pathway, as highlighted in their recent invited forum article in ***Trends in Molecular Medicine*** (https://www.cell.com/trends/molecular-medicine/abstract/S1471-4914(25)00167-4). In another study published in ***Nature Communications*** in early 2026 (https://www.nature.com/articles/s41467-026-68998-w), they further demonstrated that the homeostatic activity of this microbiota-enabled NAD^+ biosynthesis pathway is important for sustaining the NAD^+ pool needed for efficient PARP-mediated DNA repair, thereby contributing to the suppression of tumorigenesis.

Dr. **Wei Xu** and her team at the University of Wisconsin-Madison identified BRD8 as a treatment-inducible epigenetic driver of this resistance: its expression rises rapidly after anti-HER2 exposure, its loss re-sensitizes resistant tumors, and a three-gene BRD8 signature predicts treatment response in independent cohorts. This work is published in ***Cancer Research*** (Gao et al., Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer. Cancer Res. 2026 Mar 26. doi: 10.1158/0008-5472.CAN-25-4701. PMID: 41886605).

Dr. **Huiping Liu** at Northwestern University Feinberg School of Medicine was awarded Breast Cancer Alliance (BCA) Exceptional Project (XP) Grant Award in 2026. Accelerated by computational ranking and experimental investigation, her lab discovered that circulating tumor cells (CTCs) not only cluster with other CTCs, but also cluster with immune cells, such as leukocytes, especially immune-suppressive T cells (CD4+CD8+ double positive T) and monocytes, through VCAM1-integrin VLA4 axis and PlexinB2-SemaA, respectively. Genetic depletion or neutralizing antibodies against these molecular drivers inhibit CTC cluster formation and lung metastasis, thereby improving animal survival. This study was published as research articles in ***J Clinical Investigation*** 2025 (https://www.jci.org/articles/view/193521) and ***Nature Communications*** 2025 (https://www.nature.com/articles/s41467-025-62862-z).

Dr. **Shi-Yuan Cheng** at Northwestern University in Chicago discovered that increased expression of a novel long non-coding RNA named HELDR drives glioblastoma cell growth and malignancy alongside a major genetic mutation EGFR found in more than half of glioblastoma tumors. He showed that HELDR binds to promoters, gene bodies and intergenic regions to regulate global gene expression without affecting *EGFR* signaling. He further found that therapeutically targeting HELDR-driven epigenetic program enhanced treatment response to EGFRis *in vivo*. This study was published in ***Nature Cell Biology*** *https://www.nature.com/articles/s41556-026-01924-w*

Dr. **Zhenkun Lou's** group at Mayo Clinic identified several new mechanisms that preserve genome stability. They discovered that KCTD10 detects transcription–replication conflicts and recruits CUL3 to remove TCEA2, enabling replication to proceed; this work was published in ***Nature* (2025)**: https://www.nature.com/articles/s41586-025-09585-9. His group also showed that ROS-induced ADAR1

Members' Research Highlights (Cont'd)

dimerization promotes A-to-I editing of RNA primers at replication forks, supporting Okazaki fragment maturation and centromere stability; this study appeared in ***Nature Structural & Molecular Biology* (2026)**: https://www.nature.com/articles/s41594-025-01736-w. In addition, they found that the NSD3 short isoform stabilizes stalled replication forks and promotes PARP inhibitor resistance in prostate cancer; this work was published in ***Molecular Cell* (2025)**: https://doi.org/10.1016/j.molcel.2025.06.004.

Dr. **Qing Zhang** at UT Southwestern recently revealed HLF as a suppressor for lung metastasis in solid cancers a new tumor suppressor This study was published in ***Nature Communications*** (2025): https://www.nature.com/articles/s41467-025-60329-9. In addition, his lab published two papers in ***Journal of Clinical Investigation (JCI)***, one paper focusing on identifying KIF20A as a critical regulator for stem like triple-negative breast cancer (TNBC) cells and targeting KIF20A sensitizes TNBC cells to standard chemotherapy (2026): *https://www.jci.org/articles/view/182394*. The second JCI paper identified a cytokine-enhancer circuit controlling HIF2α in renal cancer (2026): https://www.jci.org/articles/view/201639. Lastly, his lab also discovered a potent and selective TBK1 PROTAC to be used for treating ccRCC and pancreatic cancer, which was published in ***Cell Chemical Biology*** (2026): https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(26)00105-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2451945626001054%3Fshowall%3Dtrue

Dr. **Di Zhao** at MD Anderson Cancer Center was promoted to Associate Professor with Tenure on Sep 1st, 2025. Her team recently reported that genetic alterations of SPOP and CHD1 play divergent roles in ACSL4 regulation and uncovered context-dependent metabolic vulnerabilities for targeting ferroptosis in advanced prostate cancer (accepted for publication in **Nature Communications;** hopefully online soon).

Dr. **Yi-Chieh Nancy Du** at Weill Cornell Medicine and colleagues reported a breakthrough in metastatic cancer therapy by showing that the metal-free carbon monoxide prodrug CO-116 suppresses metastasis of pancreatic and breast cancer in vivo. The study establishes a first-in-class, non-inhaled, metal-free CO delivery strategy and identifies heme restriction through HRG1 downregulation as a mechanistic basis for its anti-metastatic activity. This work was published in Advanced Science in 2026. https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202519898 In addition, related work in the field was highlighted by a 2025 Medicinal Research Reviews cover article, Compelling Evidence: A Critical Update on the Therapeutic Potential of Carbon Monoxide. https://onlinelibrary.wiley.com/doi/10.1002/med.22116

Dr. **Erxi Wu** at BSWH / BCM – Temple and collaborators have recently published several highly impactful studies in cancer biology, translational medicine, and microbiome therapeutics. Dr. Wu's lab developed GBM-Dx SIGNAL, a blood transcriptomics platform that improves distinction between glioblastoma recurrence and treatment-related effects when integrated with neuroimaging, thereby enhancing diagnostic accuracy for glioblastoma management (***Genes & Diseases***: https://www.sciencedirect.com/science/article/pii/S2352304226000012). He and his collaborators also identified the Src/FN1 signaling pathway as a critical mediator of lung cancer metastasis, with targeting of the Src/FN1 axis significantly suppressing tumor dissemination and highlighting a promising therapeutic strategy

Members' Research Highlights (Cont'd)

for metastatic lung cancer (***Science Advances***: https://www.science.org/doi/10.1126/sciadv.adv7377). In addition, Dr. Wu and his collaborators demonstrated that the DNA aptamer HY-4 disrupts the nucleolin-CXCR4 interaction and inhibits colorectal cancer metastasis, establishing the nucleolin-CXCR4 axis as a potential therapeutic target (***Molecular Therapy***: https://www.cell.com/molecular-therapy/fulltext/S1525-0016(25)00538-6). Dr. Wu and collaborators also led a randomized Phase 2 clinical trial demonstrating that repeated fecal microbiota transplantation significantly improves motor and gastrointestinal symptoms in Parkinson's disease patients, supporting gut microbiome modulation as a promising therapeutic strategy (***Signal Transduction and Targeted Therapy***: https://www.nature.com/articles/s41392-026-02604-9).

Association of Chinese Americans in Cancer Research

2026 Virtual Annual Meeting Seminar Series

Friday, 4:00-6:00 pm EST
(3:00-5:00 pm CST; 1:00-3:00 pm PT)

7/10/2026	**Kun Cheng** (UMKC)	**Yang Chen** (MD Anderson)
7/17/2026	**Yi Li** (Baylor)	**Jinjun Shi** (Harvard)
7/24/2026	**Yuxuan Miao** (U Chicago)	**Peng Zhang** (Northwestern)
7/31/2026	**Zhenkun Lou** (Mayo Clinic)	**Chang Jiang** (Moffitt)
8/7/2026	**Zheng Xia** (OHSU)	**Chengfei Liu** (UC Davis)
8/14/2026	**Pengda Liu** (UNC)	**Dongyin Guan** (Baylor)

Zoom Meeting Link
https://mdacc.zoom.us/j/92069181049?pwd=hFwX9WfndScIc4IsUsogWNsHnuOWrc.1

Meeting ID: 920 6918 1049
Password: 872544

Organized by the ACACR Committee

Wei Xu, University of Wisconsin; **Erxi Wu**, Baylor College of Medicine
Xiaoqi Liu, University of Kentucky; **Di Zhao**, UT MD Anderson
Qing Zhang, UT Southwestern; **Wenwei Hu**, Rutgers University
Boyi Gan, UT MD Anderson; **Shi-Yuan Cheng**, Northwestern University
Mushui Dai, Oregon Health & Science University

Genes & Diseases

An international journal for molecular and translational medicine

Journal Metrics

Impact Factor: 9.4 (2025)

Published Quarterly
Open Access
ISSN: 2352-3042

Types of Articles

Full length article, review article, short communication, correspondence, perspective, commentary, views on news, and research watch.

Editors-in-Chief

Ailong Huang and Tong-Chuan He

Deputy Editors-in-Chief

Zhenghe John Wang and Xiaodong Zhao

Review Speed



Call for Papers

Email: editor@genesndiseases.com
Home page: https://www.journals.elsevier.com/genes-and-diseases/
Journal page: https://www.sciencedirect.com/journal/genes-and-diseases

In partnership with ACACR

EINSTEIN CELL BIOLOGY | EINSTEIN Albert Einstein College of Medicine

POSTDOCTORAL POSITION

Laboratory of Dr. B. Hilda Ye, PhD

Albert Einstein College of Medicine, Bronx, NY

A POSTDOCTORAL FELLOWSHIP is available beginning August 1st, 2026, to study the molecular and cellular mechanisms of HTLV-1-driven adult T-cell leukemia/lymphoma (ATLL). Being the only human cancer caused by a retrovirus, ATLL is a fatal disease with no effective therapy. ATLL is distinguished from other types of T cell lymphomas in its unique genetic and phenotypic characteristics as well as clinical behavior. Evidence is also accumulating that ATLL diagnosed in North America and Japan may differ in their mutation patterns and in their anti-HTLV-1 host immune responses. We use patient samples, cell lines, and novel animal models to investigate the roles played by selected ATLL-driver mutations. A particular focus is on altered epigenetic regulation and rewiring of the regulatory network governing normal $CD4^+$ T cell development and differentiation. We are also characterizing functional interactions between transformed ATLL T cells and host immunity. More information about our work can be found at: https://www.einsteinmed.edu/faculty/7901/b-hilda-ye/

Recent PhD or MD graduates with significant research experience are preferred. Proficiency in molecular biology techniques, including manipulation and analysis of gene expression in cultured and primary cells, and experience with cancer animal models are essential. Some knowledge of cellular immunology and/or computational skills would be desirable. First-authored publication(s) in peer-reviewed, English language journals that demonstrate the capability to conduct discovery research are required. Ability to work independently, motivation to make novel discoveries, and a strong work ethic are important. Salary will be commensurate with experience. A curriculum vitae with a description of research experiences, a career plan, and contact information for three references should be sent to hilda.ye@einsteinmed.edu. Please make the email subject "Postdoctoral Application - Your name."

The Albert Einstein College of Medicine (Einstein) is one of the nation's premier institutions for basic research and clinical investigation with more than 300 research laboratories funded by more than $220 million from the National Institutes of Health. There are ~200 PhD students and ~250 postdoctoral fellows at Einstein https://www.einsteinmed.edu/about/ . The Department of Cell Biology is an intellectually diverse and highly interactive research community. We have a proud history of launching the careers of many talented young scientists https://www.einsteinmed.edu/departments/cell-biology/

Albert Einstein College of Medicine is an Equal Opportunity Employer.

The laboratory of **Dr. Jie Li**, Associate Professor at **The University of Texas at Austin College of Pharmacy** (https://pharmacy.utexas.edu/directory/jie-li)

in collaboration with the laboratory of **Dr. Erxi Wu**, Professor at **Baylor College of Medicine-Temple** (https://www.bswhealth.com/medical-professionals/research/cancer-agent-target-discovery-and-aptamer-development)

is seeking a highly motivated **Postdoctoral Fellow** to join an exciting interdisciplinary research program focused on **human microbiome-mediated cancer pharmacology and drug discovery**. The research will investigate the pharmacological mechanisms underlying tumor–microbiome interactions and the development of innovative therapeutic strategies.

The two laboratories offer highly complementary expertise and have published extensively in leading international journals, including *Nature Medicine, Nature Chemistry, Molecular Cancer, Signal Transduction and Targeted Therapy, Bioactive Materials, Nature Communications, Molecular Therapy, Gut Microbes,* and the *Journal of the American Chemical Society*.

Both UT Austin and Baylor College of Medicine are internationally recognized institutions with outstanding research environments. Austin, Texas, is one of the nation's leading technology and innovation hubs, offering an excellent quality of life, vibrant academic culture, and abundant opportunities for scientific collaboration.

Research Areas

- Genome mining of the human microbiome and discovery/function characterization of microbiome-derived metabolites
- Mechanistic studies of the human microbiome and its metabolites in cancer initiation and progression
- Development of novel microbiome-targeted therapeutic strategies for cancer treatment

Qualifications

Applicants should:

- Hold or expect to obtain a Ph.D. in a related field
- Have research experience in natural products, bioactivity evaluation, animal models, tumor pharmacology, or related disciplines
- Demonstrate strong independent research abilities and a track record or potential for publishing high-impact original research

Application Instructions

Interested applicants should send:

- Curriculum Vitae (CV)
- Representative publications or related materials

to:

jie.li@austin.utexas.edu
erxi.wu@bswhealth.org

CAREER DEVELOPMENT WORKSHOP IN CANCER RESEARCH

ACACR Sponsored | University of Michigan Hosts

Hosted by the University of Michigan
Join national leaders and department chairs for career guidance, research presentations, and professional networking

WHEN

August 28-30, 2026
Two-day intensive workshop

WHERE

Ann Arbor, Michigan
University of Michigan Campus

Workshop Highlights

- ✓ Social Networking Opportunities
- ✓ Invited Seminar Opportunities
- ✓ Grant Writing Tips & Strategies
- ✓ Career Development Guidance
- ✓ Leadership Path Planning
- ✓ Professional Mentorship

Presentation Eligibility & Registration

- → All assistant professors guaranteed oral presentation
- → ACACR membership required ($100 biennial or $500 lifetime)
- → Workshop registration fee: $100
- → Two-month advance registration required
- → Open to all ethnic backgrounds

Registration Opens At The End of April 2026

While sponsored by the Association of Chinese Americans in Cancer Research (ACACR), this workshop welcomes participants from all ethnic and cultural backgrounds

Dr. Shaomeng Wang

Warner-Lambert/Parke-Davis Professor of Internal Medicine
University of Michigan

Dr. Duxin Sun

Associate Dean for Research
Charles R. Walgreen Jr. Professor of Pharmacy

Dr. Weiping Zou



Director, Center of Excellence for Cancer ImmunOlogy and Immunotherapy

UNIVERSITY OF MICHIGAN

Visit the official website after the April 2026 ACACR meeting

ACACR.ORG

Why become a member of ACACR?

ACACR has two levels of membership: associate members and regular members. Associate members are members in the WeChat group, who can receive society information and participate in ACACR meetings accompanied by the annual AACR meeting. The Associate members can be removed from two WeChat groups if distributing inappropriate materials. The associate member is free of charge. The regular membership is the paid membership, which can be divided into active membership or biennial membership. The former cost is $500, the latter membership fee is $100 biennially. The benefits of being a regular member are as follows:

(1) Are eligible to be elected to the executive committee of ACACR
(2) Post job advertisement in Newsletter (Associate member will have to pay $20)
(3) Research be highlighted in the Newsletter's "Research Highlights" section
(4) Be eligible for receiving the ACACR Tony Hunter Junior and Senior Faculty Outstanding Achievement Awards
(5) Attend other research workshops organized by ACACR (e.g., career development workshop for junior faculty in 2026)
(6) Be referred by ACACR to serve on AACR committees and AACR-affiliated journals

How to make a payment to become a member?

1. Click "Pay Now" directly under Biennial Membership or Lifelong membership
2. Use Paypal to tacacr@outlook.com
3. Transfer Money (Zelle, like Chase Quickpay) to tacacr@outlook.com
4. Check pay to "Association of Chinese Americans in Cancer Research, Inc.". If you choose to pay with check, please contact Dr. Wenwei Hu, wh221@cinj.rutgers.edu, note: ACACR member
5. You will receive a receipt within 5 working days

We also encourage your generous donation to ACACR either individually (click donate button) or as meeting sponsors.

Association of Chinese Americans in Cancer Research

SCAN me to join the ACACR

ASSOCIATION OF CHINESE AMERICANS IN CANCER RESEARCH

PO Box 1382,
Timonium, MD 21093
Phone: (443) 923-9498
Email: info@acacr.org

We are on the web
http://www.acacr.org/

Our Missions

Our mission is to prevent and cure cancer through fostering interactions and collaborations among Chinese Americans in all areas of cancer research including cancer biology, etiology, genetics, epidemiology, prevention, diagnosis, and treatment. ACACR also promotes interactions and collaborations among professionals of Chinese background and/or ethnicity in cancer research through the exchange of information in education, technology, employment, and business opportunities.

Management team (web link)

Board of Directors
Shi-Yuan Cheng, PhD
Wei Gu, PhD
Yibin Kang, PhD
Jinsong Liu, MD, MA, PhD
Hua Lu, MD, PhD
Shaomeng Wang, PhD

President
Wei Xu, PhD

President Elect
Erxi Wu, PhD
Qing Zhang, PhD

General Secretary
Xiaoqi Liu, PhD

Treasurer
Wenwei Hu, PhD

Committee chair/ Co-chair
Annual meeting
Boyi Gan, PhD
Wei Xu, PhD
Erxi Wu, PhD

Audit
Mushui Dai, MD., PhD

Fundraising
Erxi Wu, PhD
Xiaoqi Liu, PhD

IT-support
Wenwei Hu, PhD
Mushui Dai, MD, PhD

Membership
Wenwei Hu, PhD
Lanjing Zhang, MD

Newsletters
Mushui Dai, MD, PhD
Qing Zhang, PhD
Nancy Du, PhD

Past Presidents
2024-2026
Boyi Gan, PhD

2023-2024
Gen-Sheng Feng, PhD

2021-2022
Lin Zhang, PhD

2019-2020
Zhenkun Lou, PhD

2017-2018
Shi-Yuan Cheng, PhD

2026 Summer Seminar Committee
Di Zhao, PhD
Wei Xu, PhD
Xiaoqi Liu, PhD
Erxi Wu, PhD

2026 Career Development Workshop Committee
Shi-Yuan Cheng, PhD
Wei Xu, PhD
Xing Fan, MD, PhD
Gensheng Wu, PhD